Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma

NCT03086993 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

295

Enrollment

INDUSTRY

Sponsor class

Conditions

Bile Duct Cancer
Intrahepatic Cholangiocarcinoma

Interventions

COMBINATION_PRODUCT: Melphalan/HDS
DRUG: Cisplatin and Gemcitabine

Sponsor

Delcath Systems Inc.